Each business day, TheStreet.com Ratings compiles a list of the top five stocks in five categories -- fast-growth, all-around value, large-cap, mid-cap and small-cap -- and publishes these lists in the Ratings section of our Web site. This list is based on data from the close of the previous trading session. Today, small-cap stocks are in the spotlight. These are stocks of companies that have market capitalizations of between $50 million and $500 million that rank near the top of all stocks rated by our proprietary quantitative model, which looks at more than 60 factors. The stocks must also be followed by at least one financial analyst who posts estimates on the Institutional Brokers' Estimate System. They are ordered by their potential to appreciate. Note that no provision is made for off-balance-sheet assets such as unrealized appreciation/depreciation of investments, market value of real estate or contingent liabilities that might affect book value. This could be material for some companies with large underfunded pension plans. Balchem ( BCPC) develops, manufactures and markets specialty performance ingredients and products for the food, feed and mechanical sterilization industries. Balchem produces choline products for both human and animal consumption. Choline, a vitamin-B complex, plays a vital role in the metabolism of fat and the building and maintaining of cell structures. Choline deficiency can result in reduced growth and perosis (a disease characterized by a deformity of the leg joint) in poultry, and fatty liver, kidney necrosis and general poor health in swine, among other symptoms. In humans, choline is recognized as playing a key role in the structural integrity of cell membranes, the processing of dietary fat, reproductive development, and neural functions such as memory and muscle function. Balchem also produces encapsulated performance ingredients for use throughout the food and animal-health industries in end products such as baked goods, refrigerated and frozen dough, processed meats, seasoning blends and confections. These performance ingredients are used to enhance nutritional fortification and improve shelf life of prepared products.
Our buy rating for Balchem has not changed since June 2003. The company reported record quarterly results in net sales and net earnings for the first quarter of fiscal 2008. Balchem achieved net sales of $56.9 million, reflecting a 35% increase compared with the year-ago quarter. Net earnings increased 35% year over year to $4.6 million. As a result, net earnings per share increased 32% to 25 cents from 19 cents in the first quarter of 2007. Management reported that the integration of several acquisitions made during fiscal 2007 have gone well and stated that the first-quarter results did not yet reflect the company's full expectations for those acquisitions. Additionally, management noted again that it expects rising raw-material costs to remain a challenge for Balchem in the near term. While the company has taken pricing steps to counteract the effects of these increased input costs, the actions taken in the first quarter did not offset all the cost increases, primarily due to timing. Overall, management expects the remainder of fiscal 2008 to continue to bring double-digit increases in sales and earnings. Bear in mind, however, that global economic issues could affect the company's results. Exponent ( EXPO) is a science and engineering consulting firm whose multidisciplinary team of scientists, physicians, engineers, and business and regulatory consultants brings together more than 70 different technical disciplines to solve complicated issues facing businesses. Its professional staff can perform in-depth scientific research and analysis or very rapid-response evaluations to provide clients with the critical information they need.
Exponent has been rated a buy since November 2001. An impressive record of EPS growth and compelling growth in net income are several of the company's strengths. For the first quarter of fiscal 2008, revenue rose by 15% year over year. Net income for the same period increased 26% to $6.4 million. Exponent reported that EPS improved 29% to 40 cents in the most recent quarter. In fact, the company has demonstrated a pattern of positive EPS growth over the past two years. Finally, return on equity improved slightly from the year-ago quarter. Driven by strong earnings growth and other factors, this stock has surged 58% over the past year. We feel that Exponent should continue to climb despite its impressive performance. The company believes that it remains well positioned to capture new opportunities for growth as it moves further into fiscal 2008. For the full year, management expects to report high single-digit to low double-digit growth in revenue as a result of plans to pursue strategic opportunities. However, Exponent's future results could be negatively impacted by any disruptive changes in both general and industry-specific economic conditions and the effects of tort reform and government regulation of the company's business. Exactech ( EXAC) develops, makes, markets, distributes and sells orthopedic implant devices, related surgical instrumentation, and biologic materials to hospitals and physicians in the U.S. and 27 other countries. It produces knee systems and other joint replacement implants. Exactech's revenues are derived primarily from sales of these implants; however, revenues from the worldwide distribution of biologic materials have increased as a percentage of total revenue.
Exactech has been rated a buy since March 2007. In the first quarter of fiscal 2008, the company reported a 34% increase in revenue over the year-ago quarter. This improvement was driven by strong growth in all major product lines and higher revenue from the company's international operations. International sales grew 67% year over year, primarily due to new distributors in Europe. Net income improved 49% to $2.8 million, or 23 cents a share, compared with $1.9 million, or 16 cents a share, in the same quarter one year prior. Looking forward to the second quarter, Exactech anticipates earnings in the range of 22 cents to 24 cents a share on expected revenue of $40 million to $43 million. However, the company is highly exposed to foreign exchange risks with its increasing share of global business, and stiff government regulation could negatively impact product approvals and therefore operating results. Pericom Semiconductor ( PSEM) designs, develops and markets high-performance interface integrated circuits (ICs) and frequency control products (FCPs) used in advanced electronic systems. Interface ICs transfer, route and time electrical signals among a system's microprocessor, memory and various peripherals and between interconnected systems. FCPs are electronic components used as time and frequency clocks in electronic products ranging from computers and telecommunications switching equipment to cell phones and televisions. Pericom's interface products increase system bandwidth. We have rated Pericom a buy since February 2007. The company reported that third-quarter earnings surged 58% year over year, bolstered by strong demand for its products. Revenue for the quarter climbed 36% to $41.2 million. Net income increased to $4.1 million, or 16 cents a share, from $2.6 million, or 10 cents a share, in the third quarter of 2007. The company expanded its Digital Video solutions by launching two new switches that allow next-generation computing platforms using dual function graphics ports to be switched between either of the high speed protocols. Pericom also launched three new signal conditioning products and expanded its Timing portfolio.
Looking ahead, management expects revenue for the fourth quarter to range from $42 million to $43.2 million, with gross margin expected to range from 37% to 38%. In addition, the company expects its operating expenses to be between $10.8 million and $11 million. However, weak demand for semiconductors, higher stock option expenses, and the highly competitive market could restrict Pericom's future growth. CAM Commerce ( CADA) designs, markets, installs and services a variety of software, hardware and other technical systems for retailers. The company offers retailing systems consisting of software, hardware, installation, training, technical support services and Web hosting services to both traditional and Web retailers. CAM Commerce also offers comprehensive payment processing solutions and services that integrate with its retailing systems and those of other suppliers. Our buy rating, in place since February 2006, is based on positive investment measures such as the company's strong revenue growth, solid financial position and stock performance, and its growth in net income. Revenue rose 23% year over year for the second quarter of fiscal 2008, and this growth appears to have helped boost earnings per share to 32 cents from 20 cents a year ago. CAM Commerce has no debt to speak of, giving it a debt-to-equity ratio of zero, which we consider a favorable sign. Net income increased 60% year over year to $1.37 million. The company declared a quarterly cash dividend of 31 cents per outstanding share to be paid on July 14, continuing its "earnings-based" dividend plan that aims to pay out 75% or more of net profit each quarter. Powered by strong earnings growth of 60% during the second quarter, the price of this stock has risen 31% over the past year. We believe CAM Commerce's stock should continue to benefit from this trend and move even higher. Bear in mind, however, that even the most promising stocks are subject to broad market declines. Our quantitative rating is based on a variety of historical fundamental and pricing data and represents our opinion of a stock's risk-adjusted performance relative to other stocks. However, the rating does not incorporate all of the factors that can alter a stock's performance. For example, it doesn't always factor in recent corporate or industry events that could affect the stock price, nor does it include recent technology developments and competitive dynamics that may affect the company. For those reasons, we believe that a rating alone cannot tell the whole story and that it should be part of an investor's overall research.